Study of lorigerlimab for advanced ovarian and other cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous or clear cell, or clear cell cancer of the endometrium, cervix, vagina, or vulva.
- Your cancer must have grown or come back after at least one prior treatment, and for platinum-resistant ovarian cancer, you must have had 1 to 3 prior treatments.
- You must have at least one tumor that can be measured on a scan.
- You need to have a tumor sample (from a past biopsy or a new one) available for testing.
- If you have a BRCA gene mutation, you must have already tried a PARP inhibitor and it stopped working or caused side effects.
- You cannot have had certain immune checkpoint inhibitor drugs before, unless you have clear cell endometrial or cervical cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
This trial tests lorigerlimab, a new immunotherapy drug, for patients with advanced pancreatic cancer who have specific genetic mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D) that affect how cells repair DNA. The drug may help your immune system attack cancer cells.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.